Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Stephen Apple's publication output changed over time?
ScholarIQpublication output · 2019–2024
Output declined50% over the shown period — from 2 works in 2019 to 1 in 2024.
2
1
1
4
1
1
201920202021202220232024
What are the most-cited papers on Stephen Apple?
ScholarIQmost cited works
Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
Jeremy M. Shefner, Terry Heiman‐Patterson, Erik P. Pioro, Martina Wiedau‐Pazos, X. Shawn Liu, Jeffrey Zhang, Wendy Agnese, Stephen Apple
Muscle & Nerve. 201974 CitationsOPEN ACCESS
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
Ammar Al‐Chalabi, Adriano Chiò, Charlotte Merrill, Gerry Oster, Rebecca Bornheimer, Wendy Agnese, Stephen Apple
Journal of Neurology Neurosurgery & Psychiatry. 202042 CitationsOPEN ACCESS
Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]
Benjamin Rix Brooks, Terry Heiman‐Patterson, Martina Wiedau‐Pazos, X. Shawn Liu, Jeffrey Zhang, Stephen Apple
PLoS ONE. 202229 CitationsOPEN ACCESS
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
Angela Genge, Gary L. Pattee, Gen Sobue, Masashi Aoki, Hiide Yoshino, Philippe Couratier, Christian Lunetta, Susanne Petri, Daniel Selness, Sachin Bidani, Manabu Hirai, Takeshi Sakata, Alejandro Salah, Stephen Apple, Art Wamil, Alexander Kalin, Carlayne E. Jackson
Muscle & Nerve. 202227 CitationsOPEN ACCESS
Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film
James Wymer, Stephen Apple, Antoinette Harrison, Bryan Alan Hill
Clinical Pharmacology in Drug Development. 202226 CitationsOPEN ACCESS
Related on ScholarIQ
Mitsubishi Group (Japan)
Institution
Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
Paper
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
Paper
Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]
Paper
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
Paper
Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film
Paper